Historical height loss, vertebral deformity, and health-related quality of life in Hiroshima cohort study.

Department of Clinical Studies, Radiation Effects Research Foundation, 5-2 Hijiyama Park, Minami-ku, Hiroshima 732-0815, Japan.
Osteoporosis International (Impact Factor: 4.17). 12/2007; 18(11):1493-9. DOI: 10.1007/s00198-007-0392-2
Source: PubMed

ABSTRACT Height loss and vertebral deformity had independent effects on health-related quality of life evaluated by the European quality-of-life five-domain questionnaire (EQ-5D) in a cohort of 2,021 elderly Japanese men and women. Height loss aggravated EQ-5D more strongly than vertebral deformity in all domains, with different patterns.
Vertebral deformity reduces the activities of daily living and quality of life, and elevates mortality. Height loss is taken to be a sign of vertebral deformity, although other factors could also cause height loss. In this study, we examined the difference in EQ-5D between elderly with height loss and with vertebral deformity.
The subjects were 2,021 men and women aged 57-101 years from the Hiroshima Cohort who underwent health examinations in 2002-03 and responded to the EQ-5D. Vertebral deformity was assessed semi-quantitative methods using lateral chest and spine radiographs. Height was measured during the routine biennial examinations, which have been conducted since 1958. We used linear regression analyses, ordered polytomous logistic regression analyses, and Bonferroni tests.
Eighty three men and 314 women had prevalent vertebral deformity. The mean height loss was 2.2 cm for men and 3.9 cm for women. Height loss > or =4 cm (P < 0.01) and vertebral deformity (P = 0.04) were independent risk factors for low EQ-5D scores, after adjustment for sex and age.
The present study showed that height loss and vertebral deformity affected EQ-5D significantly and independently in the elderly.


Available from: Naomi Masunari, May 04, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: SummaryThis study examined associations of VFx, lumbar spondylosis and knee OA with QOL in 767 men over 40years old from the ROAD study (mean, 69.7years.). Multiple regression analysis showed VFx and knee OA as significantly associated with lower PCS scores, but lumbar spondylosis was not. PurposeLittle data have been accumulated regarding associations of vertebral fracture (VFx), lumbar spondylosis and knee osteoarthritis (OA) with quality of life (QOL) in men. The purpose of the present study is to clarify the impact of these diseases on QOL parameters such as the Medical Outcomes Study Short Form 8 (SF-8) and the EuroQOL (EQ-5D). In addition, to provide greater insight into the magnitude of QOL loss, a comparison was made with cerebral stroke. MethodsFrom the 3,040 participants in the ROAD study, this study analyzed 767 men over 40years who had completed the questionnaires (mean, 69.7years.). Vertebral fracture was assessed by lateral radiography of the lumbar spine. Lumbar spondylosis and knee OA were defined as Kellgren/Lawrence grade ≥3. Cerebral stroke was assessed by self-report. ResultsMultiple regression analysis after adjustments for age, body mass index and presence of the above four diseases showed VFx was significantly associated with lower scores in physical function (PF), role physical (RP), bodily pain (BP) and vitality (VT) domains as well as physical component summary (PCS). Knee OA were significantly associated with lower scores in PF, RP, BP and PCS scores. Lumbar spondylosis was not associated with any domains of the SF-8. Lumbar spondylosis and knee OA were significantly associated with EQ-5D utility scores, but VFx was not. The impact for VFx on BP, VT and PCS scores was larger than cerebral stroke. ConclusionsThis study revealed that VFx and knee OA impaired physical QOL in men, rather than lumbar spondylosis. KeywordsQuality of life–Vertebral fracture–Lumbar spondylosis–Knee osteoarthritis–Men
    Archives of Osteoporosis 12/2010; 5(1):91-99. DOI:10.1007/s11657-010-0039-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vertebral fractures are the most common of all osteoporotic fractures and are present in a significant percentage (25%) of the population over the age of 50, resulting in > 400,000 in the US and > 1 million in Europe per year (Cooper 1995; Cummings and Melton 2002; Davies et al. 1996; Finnern and Sykes 2003; Ismail et al. 1999; Jackson et al. 2000; Melton LJ III 1997; O’Neill et al. 1996; Roy et al. 2003). Vertebral fractures are associated with an increased mortality rate (Center et al. 1999; Kado et al. 1999) and loss of independence and impaired quality of life (Burger et al. 1997; Fink et al. 2003; Nevitt et al. 1998; Schlaich et al. 1998).
    03/2008: pages 125-136;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose To systematically review the literature describing the efficacy, effectiveness, and safety of raloxifene for postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). Materials and methods Medline via PubMed and Embase was systematically searched using prespecified terms. Retrieved publications were screened and included if they described randomized controlled trials or observational studies of postmenopausal Japanese women with osteoporosis or osteopenia treated with raloxifene and reported one or more outcome measures (change in bone mineral density [BMD]; fracture incidence; change in bone-turnover markers, hip structural geometry, or blood–lipid profile; occurrence of adverse events; and change in quality of life or pain). Excluded publications were case studies, editorials, letters to the editor, narrative reviews, or publications from non-peer-reviewed journals; multidrug, multicountry, or multidisease studies with no drug-, country-, or disease-level analysis; or studies of participants on dialysis. Results Of the 292 publications retrieved, 15 publications (seven randomized controlled trials, eight observational studies) were included for review. Overall findings were statistically significant increases in BMD of the lumbar spine (nine publications), but not the hip region (eight publications), a low incidence of vertebral fracture (three publications), decreases in markers of bone turnover (eleven publications), improved hip structural geometry (two publications), improved blood–lipid profiles (five publications), a low incidence of hot flushes, leg cramps, venous thromboembolism, and stroke (12 publications), and improved quality of life and pain relief (one publication). Conclusion Findings support raloxifene for reducing vertebral fracture risk by improving BMD and reducing bone turnover in postmenopausal Japanese women with osteoporosis or osteopenia. Careful consideration of fracture risk and the risk–benefit profile of antiosteoporosis medications is required when managing patients with osteoporosis.
    Clinical Interventions in Aging 11/2014; 9:1879-1893. DOI:10.2147/CIA.S70307 · 1.82 Impact Factor